Simvastatin: a new therapeutic approach for Smith-Lemli-Opitz syndrome

Simvastatin: a new therapeutic approach for Smith-Lemli-Opitz syndrome

The Smith-Lemli-Opitz syndrome (SLOS) is caused by deficient Δ7-dehydrocholesterol reductase, which catalyzes the final step of the cholesterol biosynthetic pathway, resulting in low cholesterol and high concentrations of its direct precursors 7-dehydrocholesterol (7DHC) and 8DHC. We hypothesized th...

Full description

Bibliographic Details
Main Authors: Petr E. Jira, Ron A. Wevers, Jan de Jong, Estela Rubio-Gozalbo, Fokje S.M. Janssen-Zijlstra, Arno F.J. van Heyst, Rob C.A. Sengers, Jan A.M. Smeitink
Format: Article
Language:English
Published: Elsevier 2000-08-01
Series:Journal of Lipid Research
Subjects:
cholesterol biosynthesis
Smith-Lemli-Opitz syndrome
simvastatin
exchange transfusion
Online Access:http://www.sciencedirect.com/science/article/pii/S0022227520334428

Internet

http://www.sciencedirect.com/science/article/pii/S0022227520334428

Similar Items